Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.77 -1.6%	$3.87	$2.12 ▼ $5.80	$375.96M	1.82	1.48 million shs	1.03 million shs
OLMA Olema Pharmaceuticals	$5.46 -1.1%	$4.96	$2.86 ▼ $13.93	$374.74M	1.92	450,672 shs	302,991 shs
SRZN Surrozen	$12.19 +4.4%	$9.71	$5.90 ▼ $18.17	$104.43M	0.62	15,969 shs	33,319 shs
YMAB Y-mAbs Therapeutics	$8.55 +0.1%	$6.12	$3.55 ▼ $16.11	$388.50M	0.53	2.18 million shs	398,287 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	-5.28%	-1.31%	+34.16%	-16.78%
OLMA Olema Pharmaceuticals	0.00%	-5.21%	+2.44%	+24.66%	-53.73%
SRZN Surrozen	0.00%	+8.65%	+10.82%	+49.94%	+14.59%
YMAB Y-mAbs Therapeutics	0.00%	+0.23%	+88.74%	+80.38%	-40.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.806 of 5 stars	3.4	3.0	2.8	0.0	0.0
OLMA Olema Pharmaceuticals	2.2385 of 5 stars	3.3	0.0	3.7	2.5	0.6
SRZN Surrozen	2.581 of 5 stars	3.5	2.0	2.9	3.3	0.0
YMAB Y-mAbs Therapeutics	2.4431 of 5 stars	2.9	4.0	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.88	Moderate Buy	$10.14	169.04% Upside
OLMA Olema Pharmaceuticals	2.67	Moderate Buy	$24.00	339.56% Upside
SRZN Surrozen	3.00	Buy	$38.50	215.83% Upside
YMAB Y-mAbs Therapeutics	1.80	Reduce	$9.62	12.54% Upside

Current Analyst Ratings Breakdown

Latest SRZN, OLMA, AQST, and YMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$28.00 ➝ $29.00
8/13/2025	AQST Aquestive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2025	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $21.00
8/11/2025	OLMA Olema Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/6/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$11.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$26.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Underperform ➝ Neutral	$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$8.60

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	6.53	N/A	N/A	($0.66) per share	-5.71
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$7.14 per share	N/A
SRZN Surrozen	$10.65M	9.81	N/A	N/A	($6.55) per share	-1.86
YMAB Y-mAbs Therapeutics	$87.68M	4.43	N/A	N/A	$2.05 per share	4.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-63.87%	11/3/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$1.98	N/A	N/A	N/A	N/A	-42.58%	-38.65%	11/11/2025 (Estimated)
SRZN Surrozen	-$63.56M	-$14.42	N/A	N/A	N/A	-274.42%	-545.43%	-64.40%	11/5/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.50	N/A	N/A	N/A	-26.03%	-24.60%	-18.89%	11/14/2025 (Estimated)

Latest SRZN, OLMA, AQST, and YMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/11/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.43	-$0.51	-$0.08	-$0.51	N/A	N/A
8/8/2025	Q2 2025	SRZN Surrozen	-$1.23	-$1.14	+$0.09	$2.55	N/A	$0.98 million
8/8/2025	Q2 2025	YMAB Y-mAbs Therapeutics	-$0.27	-$0.07	+$0.20	-$0.07	$18.40 million	$19.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	3.53	3.18
OLMA Olema Pharmaceuticals	0.01	11.09	11.09
SRZN Surrozen	N/A	16.41	16.41
YMAB Y-mAbs Therapeutics	N/A	4.00	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
OLMA Olema Pharmaceuticals	91.78%
SRZN Surrozen	66.57%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	7.85%
OLMA Olema Pharmaceuticals	16.36%
SRZN Surrozen	43.50%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.72 million	91.90 million	Optionable
OLMA Olema Pharmaceuticals	70	68.63 million	57.41 million	Optionable
SRZN Surrozen	80	8.57 million	4.84 million	Not Optionable
YMAB Y-mAbs Therapeutics	150	45.44 million	36.49 million	Optionable

SRZN, OLMA, AQST, and YMAB Headlines

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?

September 1 at 10:56 AM | zacks.com

Y-mAbs Therapeutics, Inc. $YMAB Stake Lifted by Acorn Capital Advisors LLC

September 1 at 7:36 AM | marketbeat.com

Stonepine Capital Management LLC Acquires New Stake in Y-mAbs Therapeutics, Inc. $YMAB

August 26, 2025 | marketbeat.com

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $9.62

August 26, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Reduce" from Analysts

August 25, 2025 | marketbeat.com

Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 19, 2025 | globenewswire.com

Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

August 13, 2025 | insidermonkey.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPS

August 11, 2025 | marketbeat.com

XTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 10, 2025 | marketbeat.com

A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast

August 9, 2025 | benzinga.com

Y-mAbs (YMAB) Q2 Revenue Falls 14%

August 9, 2025 | aol.comA

Federated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2025 | zacks.com

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

August 8, 2025 | businesswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to Hold

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Cantor Fitzgerald

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Truist Financial

August 8, 2025 | marketbeat.com

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

August 8, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

August 7, 2025 | prnewswire.com

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 7, 2025 | businesswire.com

HC Wainwright Reiterates "Neutral" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, OLMA, AQST, and YMAB Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$3.77 -0.06 (-1.57%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.80 +0.03 (+0.69%)

As of 08/29/2025 07:26 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Olema Pharmaceuticals NASDAQ:OLMA

$5.46 -0.06 (-1.09%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.44 -0.02 (-0.37%)

As of 08/29/2025 06:51 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Surrozen NASDAQ:SRZN

$12.19 +0.51 (+4.37%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$12.18 -0.01 (-0.12%)

As of 08/29/2025 04:02 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Y-mAbs Therapeutics NASDAQ:YMAB

$8.55 +0.01 (+0.12%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.54 -0.01 (-0.06%)

As of 08/29/2025 07:07 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time